215 related articles for article (PubMed ID: 28340402)
1. Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01.
Kay L; Willems LM; Zöllner JP; Reif PS; Klein KM; Rosenow F; Strzelczyk A
Seizure; 2017 Apr; 47():81-82. PubMed ID: 28340402
[TBL] [Abstract][Full Text] [Related]
2. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.
Peltola J; Holtkamp M; Rocamora R; Ryvlin P; Sieradzan K; Villanueva V
Epilepsy Behav; 2015 Sep; 50():46-9. PubMed ID: 26114438
[TBL] [Abstract][Full Text] [Related]
3. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
4. EPICON consensus: recommendations for proper management of switching to eslicarbazepine acetate in epilepsy.
Villanueva V; Ojeda J; Rocamora RA; Serrano-Castro PJ; Parra J; Rodríguez-Uranga JJ; Bathal H; Viteri C
Neurologia (Engl Ed); 2018 Jun; 33(5):290-300. PubMed ID: 27349151
[TBL] [Abstract][Full Text] [Related]
5. Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review.
Rissardo JP; Caprara ALF
Clin Neuropharmacol; 2020; 43(3):66-80. PubMed ID: 32384309
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Amstutz U; Shear NH; Rieder MJ; Hwang S; Fung V; Nakamura H; Connolly MB; Ito S; Carleton BC;
Epilepsia; 2014 Apr; 55(4):496-506. PubMed ID: 24597466
[TBL] [Abstract][Full Text] [Related]
7. [Long-term effects of dibenzazepines on metabolic parameters: retrospective comparison of carbamazepine, oxcarbazepine and eslicarbazepine acetate in the real world].
Ley M; Principe A; Rocamora R
Rev Neurol; 2020 Jul; 71(2):54-60. PubMed ID: 32627160
[TBL] [Abstract][Full Text] [Related]
8. Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients.
Intravooth T; Staack AM; Juerges K; Stockinger J; Steinhoff BJ
Epilepsy Res; 2018 Jul; 143():7-10. PubMed ID: 29631131
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
10. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients.
Then SM; Rani ZZ; Raymond AA; Ratnaningrum S; Jamal R
Asian Pac J Allergy Immunol; 2011 Sep; 29(3):290-3. PubMed ID: 22053601
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
[TBL] [Abstract][Full Text] [Related]
12. The evidence for switching dibenzazepines in people with epilepsy.
Watkins L; O'Dwyer M; Oak K; Lawthom C; Maguire M; Thomas R; Shankar R
Acta Neurol Scand; 2020 Aug; 142(2):121-130. PubMed ID: 32249420
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
[TBL] [Abstract][Full Text] [Related]
15. [A proposal for a model to replace carbamazepine or oxcarbazepine by eslicarbazepine acetate in clinical practice].
Poza-Aldea JJ
Rev Neurol; 2016 Sep; 63(5):219-23. PubMed ID: 27569568
[TBL] [Abstract][Full Text] [Related]
16. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
17. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.
Massot A; Vivanco R; Principe A; Roquer J; Rocamora R
Neurologia; 2014 Mar; 29(2):94-101. PubMed ID: 23623701
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.
Banach M; Borowicz KK; Czuczwar SJ
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):639-48. PubMed ID: 25740561
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Rattanavipapong W; Koopitakkajorn T; Praditsitthikorn N; Mahasirimongkol S; Teerawattananon Y
Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569
[TBL] [Abstract][Full Text] [Related]
20. Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02.
Simper GS; Hò GT; Celik AA; Huyton T; Kuhn J; Kunze-Schumacher H; Blasczyk R; Bade-Döding C
J Immunol Res; 2018; 2018():5086503. PubMed ID: 30302345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
